This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Leading Dermatologist Michael P. Heffernan, M.D. And Renowned Rheumatologist Alisa E. Koch, M.D. Join Lilly Autoimmune Team

Stocks in this article: LLY

About Michael P. Heffernan, M.D.A board-certified dermatologist, Heffernan has been the principal investigator for more than 80 research studies on disorders of the skin.

Prior to his tenure in private practice, Heffernan held faculty positions at established academic institutions. At Washington University School of Medicine, he was an assistant and associate professor and director of the Dermatology Clinical Research Fellowship. He was honored at the university twice as Dermatology Teacher of the Year. More recently, he served as the chair, Department of Dermatology, at Wright State University Boonshoft School of Medicine. While there, he was appointed to the board of directors and sat on both the clinical chairs committee and executive committee.

Among his accomplishments, Heffernan served as a dermatologist in the United States Air Force and the Air Force Reserves. He has authored more than 60 publications and textbook chapters and serves on the editorial boards for leading industry publications such as the Journal of the American Academy of Dermatology and Archives of Dermatology.

Heffernan graduated Phi Beta Kappa from the University of Notre Dame with a bachelor's degree in pre-professional studies. He received his M.D. from the University of Michigan. He was a dermatology resident at Stanford University, where he served as chief resident and started his focus in clinical trials and complex medical dermatology.

"I want to thank Lilly for giving me the opportunity to help patients all over the world with life-altering skin diseases find a better quality of life," said Heffernan.

About Alisa E. Koch, M.D.Prior to holding an endowed chair at the University of Michigan, Dr. Koch held an endowed professorship, the Gallagher Professor of Arthritis Research, at Northwestern University. While there, she was awarded with the Northwestern University Distinguished Faculty Recognition. She also served as the chief of rheumatology at the Veterans Administration Chicago Health Care System, Lakeside Division, for 13 years.

Koch's research interests in the field of rheumatoid arthritis have spanned the length of her career. She is a member of more than 15 professional societies, including the Association of American Physicians. She has published more than 225 articles in a number of scientific journals, including Arthritis and Rheumatism, Science and Nature. For more than a decade, she has been the managing editor for Frontiers in Bioscience, while also sitting on a number of other editorial boards.

A board-certified rheumatologist, Koch is a member of several professional societies including the American Association for the Advancement of Science and the American College of Rheumatology. In 2011, she received the Lee C. Howley Sr. Prize of the Arthritis Foundation, one of the most esteemed awards in research in her field.

Koch attended Northwestern University Medical School's honors program in medical education, where she received her bachelor's and M.D. degrees together in six years. She completed her fellowship in rheumatology at the Northwestern University Medical School.

"I'm extremely excited about being at Lilly and look forward to working with everyone to move novel therapies forward to combat rheumatic diseases," said Koch.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,781.81 +3.66 0.02%
S&P 500 2,063.66 +2.43 0.12%
NASDAQ 4,754.2910 +5.8950 0.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs